<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327493</url>
  </required_header>
  <id_info>
    <org_study_id>2016-A00707-44</org_study_id>
    <nct_id>NCT03327493</nct_id>
  </id_info>
  <brief_title>Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Under VA ECMO</brief_title>
  <acronym>ADRECMO</acronym>
  <official_title>Impact of Adrenoreceptor Expressions on Inflammatory Pattern in Refractory Cardiogenic Shock Patients Treated by Veno-arterial Extra-Corporeal Membrane Oxygenation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Refractory cardiogenic shock is characterized by a decreased in cardiac output with
      hypo-responsiveness to increasing doses of catecholamines resulting in a profound tissular
      ischemia. VAECMO, by restoring a circulatory flow, could be associated to a major reperfusion
      syndrome which may lead some patients to multiple organ failures and death. Pathophysiology
      of this syndrome includes 1/an hyper-adrenergic state secondary to the over activation of the
      sympathetic system and 2/ a major release of pro-inflammatory cytokines. As adrenoreceptors
      are also exhibited on immunes cells, the pro-inflammatory state might be enhanced by the
      over-activation of the sympathetic system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NB : A repartition according to other ongoing study (HYPOECMO NCTNCT02754193) is planned
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Refractory cardiogenic shock patients under ECLS. Assessment at ECLS start, day 3 and Day &quot;ECLS weaning&quot; for various biological variables</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cytokines (plasma TNF α, INF γ, IL4, IL 12, IL1 IL 6 IL 10)</measure>
    <time_frame>day 0 (ECLS initiation), day 3, day &quot;ECLS weaning&quot;</time_frame>
    <description>Exposition variable will be the density of α1, α2, β1, β2, β3-adrenoreceptors on immune cells (monocytes and lymphocytes T helper)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters</measure>
    <time_frame>day 0 (ECLS initiation), day 3, day &quot;ECLS weaning&quot;</time_frame>
    <description>Arterial pressures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters</measure>
    <time_frame>day 0 (ECLS initiation), day 3, day &quot;ECLS weaning&quot;</time_frame>
    <description>heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemodynamic parameters</measure>
    <time_frame>day 0 (ECLS initiation), day 3, day &quot;ECLS weaning&quot;</time_frame>
    <description>cumulated doses of catecholamines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac output variation during a weaning ECLS procedure</measure>
    <time_frame>day 3, day &quot;ECLS weaning&quot;</time_frame>
    <description>At a constant mean arterial pressure (65-75 mmHg), measurement by echocardiography of cardiac output at 2 times:
baseline (3L/min of ECLS flow)
after 45 min at weaning output (1.5 L/min of ECLS flow) Variation of norepinephrine doses will be also recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days and 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TH1 and TH2 pattern</measure>
    <time_frame>day 0 (ECLS initation), day 3, day &quot;ECLS weaning&quot;</time_frame>
    <description>Assessment in CD3/CD4 + cells of INF γ; IL12 (TH1) and IL4 (TH2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Shock, Cardiogenic</condition>
  <condition>Extra-Corporeal-Life-Support ( ECLS)</condition>
  <condition>Autonomic Nervous System Diseases</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Refractory cardiogenic shock under ECLS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Biological</intervention_name>
    <description>We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day &quot;ECLS weaning&quot; :
Biological assessment:
Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry
Lymphocytes Th1/Th2 pattern by flow cytometry
Cytokines on plasma : Interleukin (IL) 4, IL 12, TNF α, INF γ , IL1, IL6, IL10
Clinical assessment:
Hemodynamic parameters
Cumulated doses of catecholamines
Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day &quot;ECLS weaning&quot;)</description>
    <arm_group_label>Refractory cardiogenic shock under ECLS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients in ICU

          -  Refractory cardiogenic shock

               -  Cardiogenic shock: Systolic Arterial Pressure &lt;90mmHg, or Mean Arterial Pressure
                  &lt;65mmHg, adequate volemia, peripheral hypoperfusion symptoms, cardiac index &lt; 2.2
                  l/min/m2)

               -  Refractory state: hypo responsiveness to norepinephrine AND/OR persisting
                  profound hypo perfusion clinical symptoms despite optimal resuscitation

          -  needing an Extra-Corporeal-Life-Support

          -  informed consent from relatives or patient

          -  Affiliation to a social security regimen

          -  Preliminary medical examination

        Exclusion Criteria:

          -  Patients under ECLS for a/an :

               -  Cardiotoxic poisoning

          -  Human immunodeficient Virus or Viral hepatitis C

          -  Patient &lt; 18 yo

          -  Pregnancy

          -  Patient under protective supervision
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antoine Kimmoun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antoine Kimmoun, MD</last_name>
    <phone>0033383154079</phone>
    <email>a.kimmoun@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHRU Nancy</name>
      <address>
        <city>Nancy</city>
        <zip>54000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoine Kimmoun, MD</last_name>
      <phone>0033383154079</phone>
      <email>a.kimmoun@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2017</study_first_submitted>
  <study_first_submitted_qc>October 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiogenic shock</keyword>
  <keyword>Extra-Corporeal-Life-Support (ECLS)</keyword>
  <keyword>inflammation</keyword>
  <keyword>adrenergic system</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Autonomic Nervous System Diseases</mesh_term>
    <mesh_term>Primary Dysautonomias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

